Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

34.52EUR
3:09am EST
Change (% chg)

€-0.30 (-0.86%)
Prev Close
€34.82
Open
€34.82
Day's High
€34.88
Day's Low
€34.52
Volume
13,809
Avg. Vol
508,351
52-wk High
€37.10
52-wk Low
€10.26

Latest Key Developments (Source: Significant Developments)

Ablynx to offer and sell about $175 million of its ordinary shares
Tuesday, 17 Oct 2017 07:30am EDT 

Oct 17 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING.‍INTENDS TO OFFER AND SELL ABOUT $175 MILLION OF ITS ORDINARY SHARES IN A GLOBAL OFFERING​.‍BOFA MERRILL LYNCH, J.P. MORGAN AND JEFFERIES ARE ACTING AS JOINT BOOK-RUNNING MANAGERS FOR OFFERING​.‍INVESTORS OTHER THAN QUALIFIED INVESTORS UNDER APPLICABLE LAW WILL NOT BE ELIGIBLE TO PARTICIPATE IN THIS PRIVATE PLACEMENT​.‍BAIRD, BRYAN, GARNIER & CO. AND LADENBURG THALMANN ARE ACTING AS CO-MANAGERS FOR OFFERING​.‍FINAL PRICE PER SHARE OF ORDINARY SHARES TO BE DETERMINED FOLLOWING BOOKBUILDING PROCESS​.  Full Article

Ablynx establishes subsidiary in USA
Monday, 16 Oct 2017 01:00am EDT 

Oct 16 (Reuters) - ABLYNX NV ::ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER.  Full Article

Ablynx NV files for U.S. IPO of up to $150 mln
Monday, 2 Oct 2017 05:00pm EDT 

Oct 2 (Reuters) - Ablynx NV :Ablynx NV files for U.S. IPO of up to $150.0 million ‍- SEC filing‍​.Ablynx NV says intends to apply to list ADSs on Nasdaq Global Select Market under symbol “ABLX”.Ablynx NV says BofA Merrill lynch, J.P. Morgan, Jefferies, Baird ,Bryan, Garnier & Co and Ladenburg Thalmann are underwriters to IPO.Ablynx NV - proposed IPO price is an estimate solely for purpose of calculating SEC registration fee.  Full Article

Ablynx lowers net cash burn guidance for the full year 2017
Thursday, 24 Aug 2017 01:00am EDT 

Aug 24 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE.H1 REVENUES OF €34.7 MILLION (2016: €53.1 MILLION).H1 OPERATING LOSS OF €24.8 MILLION (2016: €2.0 MILLION).H1 NET CASH BURN OF €30.9 MILLION (2016: €19.0 MILLION).H1 CASH POSITION OF €204.5 MILLION (2016: €288.7 MILLION).ON TRACK TO REPORT TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB IN PATIENTS WITH ATTP IN LATE Q3 2017.EXPECTS TO REPORT RESULTS OF ONGOING SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS BEFORE END OF YEAR.IN Q4 2017, CO PLANS TO FILE FOR REGULATORY APPROVAL TO ENABLE A PHASE II STUDY IN JAPAN WITH ALX-0171 IN INFANTS HOSPITALISED WITH A RSV INFECTION.COMPANY IS LOWERING ITS NET CASH BURN GUIDANCE FOR THE FULL YEAR 2017 AND IT IS NOW EXPECTED TO BE IN THE RANGE OF €65-75 MILLION.IN Q4 2017, WILL ALSO FILE FOR REGULATORY APPROVALS TO ENABLE GLOBAL PHASE II STUDY WITH ALX-0171 IN ADULTS WHO UNDERWENT STEM CELL TRANSPLANTATION AND BECAME INFECTED WITH RSV.  Full Article

Ablynx announces warrant exercise
Friday, 11 Aug 2017 01:00am EDT 

Aug 11 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES WARRANT EXERCISE.AS A RESULT OF THIS TRANSACTION, ABLYNX NOW HAS 61,169,732 SHARES OUTSTANDING.ADDITIONAL 16,700 COMMON SHARES HAVE BEEN ISSUED BY COMPANY IN EXCHANGE FOR EUR 80,684 AS RESULT OF EXERCISE OF WARRANTS​.  Full Article

Ablynx receives FDA fast track designation for Caplacizumab
Wednesday, 26 Jul 2017 01:00am EDT 

July 26 (Reuters) - ABLYNX NV :ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP.ABLYNX NV - ‍CAPLACIZUMAB IS CURRENTLY BEING FURTHER EVALUATED IN PHASE III HERCULES STUDY​.ABLYNX NV - ‍RESULTS FROM THIS PHASE III STUDY WILL BE REPORTED IN SECOND HALF OF 2017​.  Full Article

Ablynx issues additional 19,833 common shares
Monday, 24 Jul 2017 01:00am EDT 

July 24 (Reuters) - ABLYNX NV ::ADDITIONAL 19,833 COMMON SHARES HAVE BEEN ISSUED BY COMPANY IN EXCHANGE FOR EUR 121,444 AS RESULT OF EXERCISE OF WARRANTS.  Full Article

Ablynx and Sanofi enter into a strategic collaboration
Thursday, 20 Jul 2017 01:13am EDT 

July 20 (Reuters) - ABLYNX NV : :ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES.ABLYNX NV - ‍COLLABORATION GIVES SANOFI ACCESS TO CERTAIN NANOBODIES IN ABLYNX'S EXISTING PORTFOLIO​.ABLYNX NV - ‍SANOFI GAINS EXCLUSIVE GLOBAL RIGHTS TO CERTAIN MULTI-SPECIFIC NANOBODIES AGAINST SELECTED TARGETS​.ABLYNX NV - ‍FINANCIAL TERMS INCLUDE AN UPFRONT PAYMENT OF EUR 23 MILLION TO ABLYNX​.ABLYNX NV - ‍ABLYNX WILL RECEIVE RESEARCH FUNDING, ESTIMATED TO AMOUNT TO EUR 8 MILLION FOR INITIALLY SELECTED TARGETS​.  Full Article

Ablynx initiates study of caplacizumab in healthy Japanese subjects
Monday, 26 Jun 2017 01:00am EDT 

June 26 (Reuters) - Ablynx NV ::ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS.ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS.TO COMPARE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROFILES OF CAPLACIZUMAB IN JAPANESE AND CAUCASIAN SUBJECTS.TO EVALUATE IMMUNOGENICITY OF CAPLACIZUMAB IN JAPANESE SUBJECTS.  Full Article

Ablynx to receive 15 million euros milestone payment
Monday, 22 May 2017 01:00am EDT 

May 22 (Reuters) - ABLYNX NV ::NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT.ABLYNX ANNOUNCED THAT IT HAS COMPLETED PREPARATION OF A PRE-CLINICAL PACKAGE FOR A NOVEL NANOBODY® (ALX-1141) IN OSTEOARTHRITIS.AS PART OF ONGOING COLLABORATION BETWEEN ABLYNX AND MERCK KGAA <<>>, MERCK HAS ACCEPTED PRE-CLINICAL PACKAGE AND THIS HAS TRIGGERED A EUR 15 MILLION MILESTONE PAYMENT TO ABLYNX.MERCK IS NOW RESPONSIBLE FOR FURTHER CLINICAL DEVELOPMENT OF MOLECULE.  Full Article

Deals of the day-Mergers and acquisitions

Jan 18 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Thursday: